Alnylam Pharmaceuticals (ALNY) Work In Process (2018 - 2026)

Alnylam Pharmaceuticals' Work In Process history runs 9 years deep, the most recent figure standing at $65.5 million for Q1 2026.

• Quarterly Work In Process rose 21.24% year-over-year to $65.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $65.5 million (up 21.24% YoY) and the FY2025 annual result came in at $65.1 million, changed 0.22% from the prior year.
• Work In Process was $65.5 million for Q1 2026 at Alnylam Pharmaceuticals, up from $65.1 million in the prior quarter.
• Across five years, Work In Process topped out at $116.7 million in Q2 2023 and bottomed at $35.5 million in Q3 2025.
• A 5-year average of $79.0 million and a median of $76.1 million in 2024 frame the typical range for Work In Process.
• Annual changes were most pronounced in 2022 — Work In Process surged 295.84% — and 2025, when it tumbled 49.18%.
• Alnylam Pharmaceuticals' Work In Process stood at $113.8 million in 2022, then plunged by 32.36% to $77.0 million in 2023, then fell by 15.57% to $65.0 million in 2024, then rose by 0.22% to $65.1 million in 2025, then grew by 0.51% to $65.5 million in 2026.
• Business Quant data shows ALNY's Work In Process at $65.5 million in Q1 2026, $65.1 million in Q4 2025, and $35.5 million in Q3 2025.